Related Experiment Video

Updated: Jul 16, 2026

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids
09:43

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids

Published on: October 14, 2019

New drug development in digestive neuroendocrine tumors

I Durán1, R Salazar, O Casanovas

  • 1Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, Canada.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|February 16, 2007
PubMed

Insights

Targeted therapies show promise for gastrointestinal neuroendocrine tumors (NETs). Antiangiogenic agents and inhibitors of epidermal growth factor receptor (EGFR) and insulin growth factor receptor (IGFR) offer new treatment avenues.

Area of Science:

  • Oncology
  • Gastroenterology
  • Molecular Biology

Background:

  • Gastrointestinal neuroendocrine tumors (NETs) exhibit limited response to traditional cytotoxic chemotherapy.
  • NETs display significant tumor vascularization and overexpression of proangiogenic factors like vascular endothelial growth factor.
  • Key signaling pathways, including epidermal growth factor receptor (EGFR), insulin growth factor receptor (IGFR), and PI3K-AKT-mTOR, are dysregulated in NETs.

Purpose of the Study:

  • To discuss the rationale for antiangiogenic strategies in NET treatment.
  • To explore the potential of targeting EGFR, IGFR, and mTOR pathways in NETs.
  • To present emerging clinical trial data on targeted therapies for NETs.

Main Methods:

  • Review of biological features of NETs.
  • Discussion of antiangiogenic and targeted pharmacological strategies.
  • Analysis of recent clinical trial outcomes.

Main Results:

  • NETs present viable molecular targets due to their unique vascularization and signaling pathway profiles.
  • Targeted agents inhibiting angiogenesis, EGFR, IGFR, and mTOR pathways are under investigation.
  • Early clinical trial results indicate potential efficacy of these targeted therapies.

Conclusions:

  • Targeted therapies represent a promising approach for managing gastrointestinal NETs.
  • Further clinical investigation is warranted to establish the role of these agents in NET treatment protocols.

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...